Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092089 | 0.88 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL109045 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KMT2ATSHRHPGDMEN1 | |
| SCHEMBL15080489 | 0.81 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL16450930 | 0.81 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10105974 | 0.81 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL14860981 | 0.79 | MAPK1 (0.48) | L3MBTL1ALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL13248996 | 0.78 | MAPT (0.46) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL9315250 | 0.78 | MGLL (0.56) | ALDH1A1TSHRSMN1; SMN2RAB9AMAPT | |
| SCHEMBL317765 | 0.76 | MAPK1 (0.43) | ALDH1A1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL4393639 | 0.76 | TSHR (0.45) | ALDH1A1KMT2ATSHRMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242922-A1 | GENE EDITING TOOLS | LIFE TECHNOLOGIES CORP (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242922-A1 | GENE EDITING TOOLS | LIFE TECHNOLOGIES CORP (US) | 2023-08-03 | — | — | US | disclosed |
| US-11701433-B2 | Complexes for delivery of antigenic peptides | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701433-B2 | Complexes for delivery of antigenic peptides | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200129640-A1 | COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-30 | — | — | US | disclosed |
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701433-B2 | Complexes for delivery of antigenic peptides | IFNG, ALB, IFNAR1 | L3MBTL1 3246/4885ALDH1A1 4069/4885KMT2A 3440/4885 |
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | GRHPR, DCXR, HRH2 | L3MBTL1 4571/4885ALDH1A1 1415/4885KMT2A 4511/4885 |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | HACL2, HAAO, LIPA | L3MBTL1 4722/4885ALDH1A1 304/4885KMT2A 4044/4885 |
| US-20200129640-A1 | COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES | IFNG, ALB, IFNAR1 | L3MBTL1 3246/4885ALDH1A1 4069/4885KMT2A 3440/4885 |
| US-20100317609-A1 | Method of Producing Hydroxyalkyl Starch Derivatives | HACL2, HAAO, LIPA | L3MBTL1 4722/4885ALDH1A1 304/4885KMT2A 4044/4885 |
| US-20230242922-A1 | GENE EDITING TOOLS | DCLRE1B, DNASE1L3, FEN1 | L3MBTL1 89/4885ALDH1A1 3455/4885KMT2A 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.